The ASCO Post

Five-Year Outcomes With First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma

Researchers in the phase III CheckMate 743 trial evaluated updated efficacy and safety outcomes with first-line nivolumab plus ipilimumab vs chemotherapy in unresectable pleural mesothelioma.

Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers

“This work has been nearly a decade in the making, and it is so important because there are no available approved medications for chemotherapy-induced thrombocytopenia, which drastically increases a patient’s risk of major or life-threatening bleeding.”

Addition of Tislelizumab to Chemotherapy in Recurrent or Metastatic Nasopharyngeal Cancer

Researchers evaluated the 3-year efficacy and safety of tislelizumab plus chemotherapy in recurrent or metastatic nasopharyngeal cancer in the phase III RATIONALE-309 study. At an earlier analysis, the tislelizumab group had significantly improved progression-free survival, the primary endpoint of the trial.

Women More Likely to Survive Cancer—But Suffer More Severe Side Effects

Female patients with cancer had a 21% lower risk of death compared with male patients, yet a 12% higher risk of severe toxicities, according to results from an international study.

Forgotten Lessons From South Africa

“On March 10, 2000, it was a cold Friday morning in Washington, DC. As usual, we the oncology fellows and faculty crowded into a conference room at the NIH Clinical Center in Building 10 for our weekly conference. Before the session formally began, a senior faculty member walked in holding the New York Times, opened to the science section, and read aloud: 'Cancer Researcher in South Africa Who Falsified Data Is Fired,'” writes Jame Abraham, MD, FACP.

Five-Year Outcomes With First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma

Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers

Addition of Tislelizumab to Chemotherapy in Recurrent or Metastatic Nasopharyngeal Cancer

Women More Likely to Survive Cancer—But Suffer More Severe Side Effects

Forgotten Lessons From South Africa

Matthew Strickland, MD, on locally advanced gastric/GEJ cancer: Tislelizumab plus chemoradiotherapy

AI Model for CNS Tumor Diagnosis

Advanced NSCLC: Can Automated Biomarker Based on Serial CT Scans Benefit Clinical Decision-Making?